Lilly Hand in Hand Sigilon: Cell Therapy for Type I Diabetes
April 8, 2018 Source: CPhI Pharma Online Author: Dopine
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];On April 4, Lilly and Sigilon reached a cooperative development agreement for diabetes cell therapy, and Sigilon will use the unique AfibromerTM technology to develop type 1 diabetes cell therapy. Cell therapy products are becoming more mature in the field of oncology, but how are cell therapies and diabetes involved? Here I will briefly introduce the cooperation between Lilly and Sigilon and share the Sigilon AfibromerTM technology.
First, how cell therapy treats diabetes
The breakthrough of cell therapy represented by CAR-T in the field of cancer is remarkable. Cell therapy has many possibilities. Cell therapy for diabetes is a new field.
In June 2017, Flagship Pioneering invested $23.5 million to create Sigilon. The company is dedicated to the development of innovative stem cell therapies for blood and endocrine diseases. Daniel G. Anderson and Robert Langer have established the company's unique AfibromerTM technology.
So what is the core of AfibromerTM technology?
AfibromerTM technology = unique cell line + new polymerization chemistry technology
Compared with traditional therapy, AfibromerTM technology has the advantages that can not be ignored: 1. Improve patient compliance, get rid of frequent medication; 2. Establish a more close to the physiological environment; 3. Improve the safety and effectiveness of hepatocyte therapy; 4. Broaden the field of application of cell therapy.
AfibromerTM technology can be said to be a modified version of stem cell therapy. Sigilon has a unique cell line with high expression of target protein, easy transfection, high activity and good safety. AfibromerTM chemical encapsulation technology reduces allogeneic stem cell immune rejection while avoiding fibrotic reactions.
Second, Eli Lilly invests in Sigilon to develop innovative cell therapy for diabetes
Lilly has a significant market share in the field of diabetes, and this time Lai Lai invested in Sigilon to develop innovative cell therapy for diabetes. Pursuant to the agreement, Lilly will pay a down payment of US$63 million, will invest in Sigilon, and receive exclusive worldwide license for Sigilon's AfibromerTM technology; Sigilon will be responsible for product development and all costs before the product IND, and Lilly will be responsible for the product. Clinical and commercial development, and is expected to pay up to $410 million in milestone payments and product royalties.
HSG Catheter,silicone HSG catheter,Catheter,HSG
Anesthesia Medical Co., Ltd. , https://www.honestymed.com